<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179410</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00080869</org_study_id>
    <nct_id>NCT03179410</nct_id>
  </id_info>
  <brief_title>PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer</brief_title>
  <acronym>PICK-NEPC</acronym>
  <official_title>PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew J. Armstrong, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of avelumab in patients with&#xD;
      metastatic neuroendocrine-like prostate cancer. Eligible men will be started on avelumab&#xD;
      every 2 weeks and will stay on therapy until progression or intolerable side effects. The&#xD;
      central hypothesis is that PD-L1 inhibition with avelumab will be efficacious based on&#xD;
      radiographic responses in a subset of men with metastatic neuroendocrine-like prostate cancer&#xD;
      and be reasonably well tolerated, meeting criteria for further study in larger phase 2 and 3&#xD;
      trials based on meeting pre-specified efficacy rates and prolonged PFS in some men.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Actual">December 18, 2020</completion_date>
  <primary_completion_date type="Actual">January 9, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Overall Response as Determined by iRECIST</measure>
    <time_frame>baseline to end of treatment (approximately 6 months)</time_frame>
    <description>Overall response rate is determined by radiographic response assessment utilizing modified Prostate Cancer Working Group 3 (PCWG3) using Immune Response Evaluation Criteria In Solid Tumors Criteria (iRECIST 1.1). iRECIST is the modified RECIST 1.1 for immune-based therapeutics, to measure radiographic response rate in men with metastatic prostate cancer. Patients alive who had not progressed as of the last follow-up, had PFS censored at the last follow-up date. There are five categories overall responses:&#xD;
iCR: immune complete response achieved with disappearance of all target lesions iCPD: immune confirmed progressive disease when there is either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions iSD: immune stable disease in the absence of CR or PD iUPD: immune unconfirmed progressive disease when PD is unconfirmed NE: not evaluable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of PD-L1 Inhibition With Avelumab as Determined by RECIST1.1</measure>
    <time_frame>baseline to end of treatment (approximately 6 months)</time_frame>
    <description>Overall response rate is determined by radiographic response assessment utilizing Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1). Patients alive who had not progressed as of the last follow-up, had PFS censored at the last follow-up date. There are four overall response categories:&#xD;
Complete Response (CR): disappearance of all target and non-target lesions Progressive Disease (PD): 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions Stable Disease (SD): In the absence of CR and PD Unevaluable (NE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Progression Free Survival (rPFS)</measure>
    <time_frame>baseline to end of treatment (approximately 6 months)</time_frame>
    <description>Radiographic progression free survival (rPFS) as determined by PCWG3 and RECISTS1.1 criteria. Radiographic progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median rPFS was estimated using a Kaplan-Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 23.5 months</time_frame>
    <description>Length of patient's life after starting study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and Safety of PD-L1 Inhibition With Avelumab in Men With Metastatic Neuroendocrine-like Prostate Cancer</measure>
    <time_frame>28 days post-treatment (approximately 7 months)</time_frame>
    <description>Number of Participants with Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Neuroendocrine prostate cancer (NEPC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with neuroendocrine prostate cancer (NEPC). Avelumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>10 mg/kg intravenously every 2 weeks</description>
    <arm_group_label>Neuroendocrine prostate cancer (NEPC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Neuroendocrine-like prostate cancer, based on histology OR based on clinical&#xD;
             presentation as defined by meeting one of the two below criteria. All subjects must&#xD;
             submit their primary tumor or metastatic biopsy pathology specimens to the Duke Cancer&#xD;
             Institute where they will be centrally reviewed by Duke Pathology. Central Duke&#xD;
             pathologic review is not required for screening but rather for confirmation of&#xD;
             histologic subtype. Local pathologic review is sufficient for eligibility&#xD;
             determination.&#xD;
&#xD;
               1. Criterion 1: Presence of 1 of 3 histologically proven diagnoses: 1) Primary small&#xD;
                  cell carcinoma of the prostate, defined by classic histologic features such as&#xD;
                  small tumor cells with scanty cytoplasm, darkly stained nuclei with homogeneous&#xD;
                  chromatin pattern. The tumor cells do not form glandular structure but grow as&#xD;
                  solid sheets with frequent mitotic figures and necrosis; 2) Intermediate atypical&#xD;
                  carcinoma of the prostate, which has histologic features distinct from small cell&#xD;
                  carcinoma or adenocarcinoma. The tumor grows as solid sheets or vague glandular&#xD;
                  structures. The tumor cells have moderate amounts of cytoplasm and centrally&#xD;
                  located, round and regular nuclei with fine, granular and homogeneous chromatin.&#xD;
                  Mitosis and necrosis are absent; 3) mixed histology tumors of the prostate,&#xD;
                  containing both adenocarcinoma and neuroendocrine or small cell components.&#xD;
&#xD;
               2. Criterion 2: Presence of histologically proven adenocarcinoma of the prostate&#xD;
                  without any sign of neuroendocrine or small cell histology that is&#xD;
                  radiographically progressing despite castrate levels of testosterone (&lt;50 ng/mL)&#xD;
                  with the following poor risk features:&#xD;
&#xD;
             i. Prior progression despite therapy with either abiraterone acetate and/or&#xD;
             enzalutamide ii. At least one of the following: 1) Liver metastases; 2) Bulky&#xD;
             radiographic progression (≥2 cm short axis lymph nodes or ≥1 cm long axis visceral&#xD;
             metastases) combined with low serum PSA (&lt;10ng/mL); 3) High serum LDH (&gt;1X upper limit&#xD;
             of normal).&#xD;
&#xD;
          2. Measurable disease as defined by modified PCWG3 using iRECIST criteria&#xD;
&#xD;
          3. Available tumor tissue for pathologic review and correlative studies. Tumor tissue&#xD;
             (localized or metastatic) does not need to be received but rather identified and&#xD;
             available (slides and/or blocks) to be sent to Duke.&#xD;
&#xD;
          4. Documented progressive metastatic CRPC based on at least one of the following&#xD;
             criteria:&#xD;
&#xD;
               1. PSA progression defined as 25% increase over baseline value with an increase in&#xD;
                  the absolute value of at least 2.0 ng/mL that is confirmed by another PSA level&#xD;
                  with a minimum of a 1 week interval and a minimum PSA of 2.0 ng/mL. Note: If&#xD;
                  confirmed rise is the only indication of progression, a minimal starting value of&#xD;
                  1.0 ng/mL is acceptable, unless pure small-cell carcinoma.&#xD;
&#xD;
               2. Soft-tissue progression based on new lesions or growth of existing soft tissue&#xD;
                  metastases.&#xD;
&#xD;
               3. Progression of bone disease (evaluable disease) or (new bone lesion(s)) by bone&#xD;
                  scan.&#xD;
&#xD;
          5. Castrate levels of serum total testosterone (&lt;50 ng/dl) OR ongoing documented ADT&#xD;
             unless pure small cell prostate cancer is present.&#xD;
&#xD;
          6. Previous use of radiation to metastatic site(s) at any time prior to enrollment is&#xD;
             allowed, provided that this site is not the only measurable disease present or unless&#xD;
             that solitary site is progressing following radiation.&#xD;
&#xD;
          7. Patients should have received at least one line of approved chemotherapy and/or&#xD;
             hormonal therapy&#xD;
&#xD;
          8. Previous cytotoxic chemotherapy including cisplatin, carboplatin, oxaliplatin,&#xD;
             etoposide, docetaxel, cabazitaxel, and gemcitabine is allowed, up to 3 prior regimens.&#xD;
&#xD;
          9. Karnofsky performance status of 70 or higher.&#xD;
&#xD;
         10. Acceptable initial laboratory values within 14 days of Cycle 1 Day 1 according to the&#xD;
             below table:&#xD;
&#xD;
             ANC ≥ 1500/µl Hemoglobin ≥ 9.0 g/dL(prior transfusion permitted) Platelet count ≥&#xD;
             100,000/µl Creatinine ≤ 2.0 x the institutional upper limit of normal (ULN) OR&#xD;
             creatinine clearance &gt;30 ml/min Potassium ≥ 3.5 mmol/L (within institutional normal&#xD;
             range) Bilirubin ≤ 1.5 x ULN (unless documented Gilbert's disease) SGOT (AST) ≤ 2.5x&#xD;
             ULN, or &lt;5x ULN in patients with documented liver metastases SGPT (ALT) ≤ 2.5x ULN or&#xD;
             &lt;5x ULN in patients with documented liver metastases&#xD;
&#xD;
         11. Age &gt;18&#xD;
&#xD;
         12. Highly effective contraception for male subjects with childbearing potential&#xD;
             throughout the study and for at least 60 days after last avelumab treatment&#xD;
             administration if the risk of conception exists.&#xD;
&#xD;
         13. Willing and able to provide written informed consent and HIPAA authorization for the&#xD;
             release of personal health information.&#xD;
&#xD;
         14. Life expectancy of over 3 months as determined by treating physician.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior usage of PD-1 inhibitors, programed-death ligand 1 and/or 2 inhibitors, CTLA-4&#xD;
             inhibitors including but not limited to ipilimumab, nivolumab, avelumab, durvalumab,&#xD;
             tremelimumab, and pembrolizumab.&#xD;
&#xD;
          2. Active on-going immunologic or autoimmune disease including but not limited to&#xD;
             systemic or cutaneous lupus erythematosus, cutaneous psoriasis, psoriatic arthritis,&#xD;
             rheumatoid arthritis, scleroderma, sicca syndrome, polymyalgia rheumatica,&#xD;
             polyarteritis nodosa, granulomatous polyangiitis, microscopic polyangiitis,&#xD;
             polyarteritis nodosa, temporal arteritis, giant cell arteritis, dermatomyositis,&#xD;
             Kawasaki disease.&#xD;
&#xD;
          3. Previous malignancy within 3 years other than non-melanomatous skin cancers or cancers&#xD;
             of low malignant potential such as non-invasive urothelial carcinoma.&#xD;
&#xD;
          4. Any other on-going chemotherapeutic, biologic, radiopharmaceutical, or investigational&#xD;
             agent currently or within 28 days of Cycle 1 Day 1.&#xD;
&#xD;
          5. Prior use of abiraterone and other hormonal agents used to treat prostate cancer are&#xD;
             permitted but abiraterone acetate should be stopped prior to study treatment&#xD;
             initiation.&#xD;
&#xD;
          6. Current usage of immunosuppressant medication except for a) intranasal, inhaled, and&#xD;
             topical corticosteroids and b) systemic corticosteroids equivalent to ≤ 10 mg/day of&#xD;
             prednisone, c) steroids as premedication for hypersensitivity reactions (e.g. CT scan&#xD;
             premedication).&#xD;
&#xD;
          7. Prior organ transplantation including allogeneic stem-cell transplants.&#xD;
&#xD;
          8. Active bacterial or viral infections requiring systemic therapy.&#xD;
&#xD;
          9. Current active infections with HIV/AIDS, Hepatitis B, and Hepatitis C requiring&#xD;
             treatment.&#xD;
&#xD;
         10. Live virus vaccination within 4 weeks of the first dose of avelumab (inactivated&#xD;
             vaccines are allowed).&#xD;
&#xD;
         11. Known prior hypersensitivity to the investigational product or any component&#xD;
             formulations, including known severe hypersensitivity reactions to monoclonal&#xD;
             antibodies.&#xD;
&#xD;
         12. Clinically significant (i.e. active) cardiovascular disease: cerebral vascular&#xD;
             accident (&lt;6 months prior to enrollment), myocardial infarction (&lt;6 months prior to&#xD;
             enrollment), unstable angina, congestive heart failure (≥ New York Heart Association&#xD;
             Classification Class II), or serious cardiac arrhythmia requiring medication.&#xD;
&#xD;
         13. Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade &gt; 1); however,&#xD;
             alopecia, sensory neuropathy Grade ≤ 2, Grade 2 anemia, or other Grade ≤ 2 not&#xD;
             constituting a safety risk based on investigator's judgment are acceptable.&#xD;
&#xD;
         14. Other severe acute or chronic medical conditions including colitis, inflammatory bowel&#xD;
             disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent&#xD;
             (within the past year) or active suicidal ideation or behavior; or laboratory&#xD;
             abnormalities that may increase the risk associated with study participation or study&#xD;
             treatment administration or may interfere with the interpretation of study results&#xD;
             and, in the judgment of the investigator, would make the patient inappropriate for&#xD;
             entry into this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Armstrong, MD, ScM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <results_first_submitted>December 16, 2020</results_first_submitted>
  <results_first_submitted_qc>February 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2021</results_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Andrew J. Armstrong, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>metastatic castrate-resistant prostate cancer (mCRPC)</keyword>
  <keyword>neuroendocrine prostate cancer (NEPC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03179410/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03179410/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Arm-arm Phase II Study of Avelumab</title>
          <description>Subjects with metastatic neuroendocrine-like prostate cancer will be treated with Avelumab intravenously at a dose of 10 mg/kg every 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm-arm Phase II Study of Avelumab</title>
          <description>Subjects with metastatic neuroendocrine-like prostate cancer will be treated with Avelumab intravenously at a dose of 10 mg/kg every 2 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" lower_limit="51" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior PSA</title>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.6" lower_limit="0.0" upper_limit="393.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status Score</title>
          <description>Karnofsky score for performance (KPS) status calculator scale runs from 100 to 0 where 100 means the patient's condition is normal and 0 indicates death. Higher the score, better is the condition.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90" lower_limit="80" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Overall Response as Determined by iRECIST</title>
        <description>Overall response rate is determined by radiographic response assessment utilizing modified Prostate Cancer Working Group 3 (PCWG3) using Immune Response Evaluation Criteria In Solid Tumors Criteria (iRECIST 1.1). iRECIST is the modified RECIST 1.1 for immune-based therapeutics, to measure radiographic response rate in men with metastatic prostate cancer. Patients alive who had not progressed as of the last follow-up, had PFS censored at the last follow-up date. There are five categories overall responses:&#xD;
iCR: immune complete response achieved with disappearance of all target lesions iCPD: immune confirmed progressive disease when there is either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions iSD: immune stable disease in the absence of CR or PD iUPD: immune unconfirmed progressive disease when PD is unconfirmed NE: not evaluable</description>
        <time_frame>baseline to end of treatment (approximately 6 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm-arm Phase II Study of Avelumab</title>
            <description>Subjects with metastatic neuroendocrine-like prostate cancer will be treated with Avelumab intravenously at a dose of 10 mg/kg every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Response as Determined by iRECIST</title>
          <description>Overall response rate is determined by radiographic response assessment utilizing modified Prostate Cancer Working Group 3 (PCWG3) using Immune Response Evaluation Criteria In Solid Tumors Criteria (iRECIST 1.1). iRECIST is the modified RECIST 1.1 for immune-based therapeutics, to measure radiographic response rate in men with metastatic prostate cancer. Patients alive who had not progressed as of the last follow-up, had PFS censored at the last follow-up date. There are five categories overall responses:&#xD;
iCR: immune complete response achieved with disappearance of all target lesions iCPD: immune confirmed progressive disease when there is either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions iSD: immune stable disease in the absence of CR or PD iUPD: immune unconfirmed progressive disease when PD is unconfirmed NE: not evaluable</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>iCR: immune complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>iCPD: immune confirmed progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>iSD: immune stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>iUPD: immune unconfirmed progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NE: not evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of PD-L1 Inhibition With Avelumab as Determined by RECIST1.1</title>
        <description>Overall response rate is determined by radiographic response assessment utilizing Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1). Patients alive who had not progressed as of the last follow-up, had PFS censored at the last follow-up date. There are four overall response categories:&#xD;
Complete Response (CR): disappearance of all target and non-target lesions Progressive Disease (PD): 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions Stable Disease (SD): In the absence of CR and PD Unevaluable (NE)</description>
        <time_frame>baseline to end of treatment (approximately 6 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm-arm Phase II Study of Avelumab</title>
            <description>Subjects with metastatic neuroendocrine-like prostate cancer will be treated with Avelumab intravenously at a dose of 10 mg/kg every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of PD-L1 Inhibition With Avelumab as Determined by RECIST1.1</title>
          <description>Overall response rate is determined by radiographic response assessment utilizing Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1). Patients alive who had not progressed as of the last follow-up, had PFS censored at the last follow-up date. There are four overall response categories:&#xD;
Complete Response (CR): disappearance of all target and non-target lesions Progressive Disease (PD): 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions Stable Disease (SD): In the absence of CR and PD Unevaluable (NE)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unevaluable (NE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiographic Progression Free Survival (rPFS)</title>
        <description>Radiographic progression free survival (rPFS) as determined by PCWG3 and RECISTS1.1 criteria. Radiographic progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median rPFS was estimated using a Kaplan-Meier curve.</description>
        <time_frame>baseline to end of treatment (approximately 6 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm-arm Phase II Study of Avelumab</title>
            <description>Subjects with metastatic neuroendocrine-like prostate cancer will be treated with Avelumab intravenously at a dose of 10 mg/kg every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Radiographic Progression Free Survival (rPFS)</title>
          <description>Radiographic progression free survival (rPFS) as determined by PCWG3 and RECISTS1.1 criteria. Radiographic progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median rPFS was estimated using a Kaplan-Meier curve.</description>
          <units>month</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.6" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Length of patient's life after starting study</description>
        <time_frame>Up to 23.5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm-arm Phase II Study of Avelumab</title>
            <description>Subjects with metastatic neuroendocrine-like prostate cancer will be treated with Avelumab intravenously at a dose of 10 mg/kg every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Length of patient's life after starting study</description>
          <units>month</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="2.8" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity and Safety of PD-L1 Inhibition With Avelumab in Men With Metastatic Neuroendocrine-like Prostate Cancer</title>
        <description>Number of Participants with Adverse Events</description>
        <time_frame>28 days post-treatment (approximately 7 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm-arm Phase II Study of Avelumab</title>
            <description>Subjects with metastatic neuroendocrine-like prostate cancer will be treated with Avelumab intravenously at a dose of 10 mg/kg every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity and Safety of PD-L1 Inhibition With Avelumab in Men With Metastatic Neuroendocrine-like Prostate Cancer</title>
          <description>Number of Participants with Adverse Events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 days post last day of dosing</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single Arm-arm Phase II Study of Avelumab</title>
          <description>Subjects with metastatic neuroendocrine-like prostate cancer will be treated with Avelumab intravenously at a dose of 10 mg/kg every 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC Version 5.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other Specify; Brain mets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other Specify; Brain mass removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTC Version 5.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, Specify: DIPLOPIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, Specify: TOOTH FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, Specify: C. DIF</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Investigations - Other, Specify: POSITIVE FOR BLOOD IN STOOL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Buttock pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, Specify: GROIN STRAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, Specify: MUSCLE CRAMPS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, Specify: CAUDA EQUINA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urine discoloration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, Specify: YAWNING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nail discoloration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, Specify: ABRASION RIGHT ELBOW</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, Specify: LEFT NOSTRIL SCAB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, Specify: MONS PUBIS (HERPES)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, Specify: RASH LEFT KNEE, MACULO-PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, Specify: WOUND ON BACK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, Specify: RIGHT PERCUTANEOUS NEPHROSTOMY TUBE PLACED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Armstrong, M.D.</name_or_title>
      <organization>Duke University</organization>
      <phone>919-668-8797</phone>
      <email>andrew.armstrong@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

